Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China’s efforts ... local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

This summary covers recent developments in health from the death tied to a cyberattack on Synnovis services in the UK, the Eli Lilly and Novo Nordisk rivalry in the weight-loss drug market in India, ...

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm. The range overlaps with data from Lilly, which reported 8.6% to 12.6% ...

The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with Corxel Pharmaceuticals and Sciwind Biosciences among the companies to share ...